Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Niger J Clin Pract ; 20(4): 433-437, 2017 04.
Artigo em Inglês | MEDLINE | ID: mdl-28406123

RESUMO

OBJECTIVE: It was aimed to determine whether levels of glial fibrillary acidic protein (GFAP) and Galectin-3 contribute to the diagnosis of cerebral infarction in clinically suspected ischemic stroke patients with normal computerized cranial tomography (CCT) in the emergency department. MATERIALS AND METHODS: In this study, patients above the age of 18 years who presented to emergency department of Firat University between December 2011-November 2012 and were diagnosed with cerebral infarction were included. Exclusion criteria were as follows: symptom onset exceeding 24 hours, trauma, pregnancy, acute myocardial infarction, acute pulmonary embolism, chronic renal insufficiency and steroid therapy. RESULTS: A total of 90 participants, forty patients with ischemic infarction who were diagnosed by CCT and clinical findings (Normal CCT in 17 patients and CCT with an area of infarction in 23 patients) and fifty healthy controls, were included in this study. Compared with the control group, levels of Galectin-3 and GFAP were found to be significantly increased in patients with ischemic infarction (P <0.001 and P = 0.01, respectively). It was found that levels of Galectin-3 and GFAP were significantly increased in ischemic stroke patients with normal CCT compared to the control group (P = 0.04 and P = 0.025, respectively). In ROC curve analysis, we detected %70.59 sensitivity and 70% specificity (AUC = 0.684, P = 0.0213, 95% CI: 0,558-0.792) with a cutoff value of 33.24 ng/ml for GFAP and 76.47% sensitivity and 68% specificity (AUC = 0.734, P = 0.0048, 95% CI: 0.611-0.834) with a cutoff value of 0.84 ng/ml for Galectin-3. No correlation was found between National Institutes of Health Stroke Scale (NIHSS) scores and Galectin-3 and GFAP (r = 0.251, P = 0.118 and r = 0.164, P = 0.311, respectively). CONCLUSION: The levels of Galectin-3 and GFAP were increased in acute ischemic stroke patients.


Assuntos
Encéfalo/diagnóstico por imagem , Infarto Cerebral/diagnóstico , Galectina 3/sangue , Proteína Glial Fibrilar Ácida/sangue , Tomografia Computadorizada por Raios X/métodos , Idoso , Biomarcadores/sangue , Proteínas Sanguíneas , Infarto Cerebral/sangue , Feminino , Seguimentos , Galectinas , Humanos , Masculino , Curva ROC , Estudos Retrospectivos
2.
Z Gastroenterol ; 48(2): 258-63, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20127601

RESUMO

Hepatitis B virus reactivation during immunosuppressive therapies can lead to liver failure with very limited treatment options available. We report here on two cases of severe hepatitis B reactivation during chemotherapy including rituximab for B cell lymphoma which were treated with liver or liver-cell transplantation. Liver function was normal and HBV infection was unknown in both patients before chemotherapy was started. Impaired liver function became apparent after 4 and 6 courses of chemotherapy, respectively, and both patients experienced fulminant hepatic failure despite antiviral treatment with lamivudine or entecavir. Patient A underwent liver transplantation after documentation of complete remission of the lymphoma and survived without any evidence for hepatitis B recurrence. Patient B received 4 courses of hepatocyte transplantation but did not survive. These cases underline the importance of anti-HBc screening in patients receiving immunosuppressive treatments in particular when rituximab is given. Pre-emptive antiviral treatments should be administered since delayed antiviral treatment is frequently unable to prevent liver failure.


Assuntos
Anticorpos Monoclonais/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Hepatite B/induzido quimicamente , Fatores Imunológicos/efeitos adversos , Falência Hepática/induzido quimicamente , Linfoma de Zona Marginal Tipo Células B/tratamento farmacológico , Linfoma de Células B/tratamento farmacológico , Neoplasias Gástricas/tratamento farmacológico , Ativação Viral/efeitos dos fármacos , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais Murinos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Antivirais/uso terapêutico , Transplante de Células , Ciclofosfamida/efeitos adversos , Ciclofosfamida/uso terapêutico , Doxorrubicina/efeitos adversos , Doxorrubicina/uso terapêutico , Evolução Fatal , Hepatite B/terapia , Hepatócitos/transplante , Humanos , Fatores Imunológicos/administração & dosagem , Falência Hepática/terapia , Transplante de Fígado , Masculino , Pessoa de Meia-Idade , Prednisona/efeitos adversos , Prednisona/uso terapêutico , Rituximab , Vincristina/efeitos adversos , Vincristina/uso terapêutico
3.
Appl Radiat Isot ; 61(4): 517-23, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15246392

RESUMO

Boron alloyed stainless-steel sheets are predominantly used in nuclear engineering as neutron shielding for radioactive waste disposal equipment. The neutron absorption depends strongly on the amount and the distribution of the 10B isotope. A systematic transmission study of 10B enriched steel plates by means of neutron time-of-flight and neutron radiography experiments was performed. The 10B content was analyzed with accuracy up to 5 x 10(-3) wt% using monochromatic beams and a linear increase of the macroscopic cross section with the 10B content was found even for strong absorbers. Then we extended the transmission analysis to "white" thermal neutron beams where large deviations from the exponential transmission law are observed. The influence of the spectral width is discussed in more detail because beam hardening causes an elevation of the effective transmission through strong absorbing materials, an effect which is crucial for the design of neutron shielding.

5.
Psychoneuroendocrinology ; 26(6): 641-7, 2001 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-11403983

RESUMO

It has been proposed that new atypical antipsychotics cause minimal prolactin (PRL) elevation compared to traditional antipsychotic agents because they spare dopamine blockade within the brain's tuberoinfundibular tract. The aim of this study was to compare the effects of olanzapine and haloperidol on PRL secretion in male schizophrenic patients. Twenty-nine male schizophrenic inpatients were included in the study. Fifteen of them were given olanzapine in a fixed dose of 10 mg/day PO and 14 of them were given haloperidol in a fixed dose of 10 mg/day PO for 6 weeks after a 2-week drug washout period. Fifteen age-matched healthy control subjects were used as control group. PRL levels were measured both before and after the 6-week treatment period in the patients. At the end of the 6th week, the PRL values observed with olanzapine treatment were significantly less than those observed with haloperidol, but not different from those of the controls. There was a significant positive correlation between the PRL values and the severity of extrapyramidal side effects in only the haloperidol group after the six week's treatment period. Our data indicate that short-term olanzapine treatment at doses of 10 mg/day PO causes minimal elevations in PRL secretion in male schizophrenic patients in contrast to haloperidol. This finding is consistent with the previous reports and may be attributed to olanzapine's differential effects on dopamine neurotransmission.


Assuntos
Antipsicóticos/efeitos adversos , Haloperidol/efeitos adversos , Pirenzepina/efeitos adversos , Prolactina/sangue , Esquizofrenia/sangue , Adulto , Antipsicóticos/administração & dosagem , Antipsicóticos/uso terapêutico , Benzodiazepinas , Haloperidol/administração & dosagem , Haloperidol/uso terapêutico , Humanos , Masculino , Olanzapina , Pirenzepina/administração & dosagem , Pirenzepina/análogos & derivados , Pirenzepina/uso terapêutico , Prolactina/metabolismo , Esquizofrenia/tratamento farmacológico
6.
Artigo em Inglês | MEDLINE | ID: mdl-11294478

RESUMO

1. In this study, the authors sought to test the hypothesis that Li (lithium) treatment can induce alterations in PRL (prolactin) secretion in euthymic bipolar patients compared to controls and that short and long-term administration can lead to prolactin changes different from each other. 2. Twenty euthymic bipolar male patients on long-term lithium carbonate treatment for more than 6 months and 15 euthymic male bipolar patients on short-term Li treatment for shorter than 6 months who met DSM-IV criteria for bipolar affective disorder were included in the study. Seventeen age-matched healthy control males were chosen among the hospital staff. The mean +/- SD duration of Li use was 68.93+/-46.31 months in the long-term lithium-treated group and 4+/-3.42 months in the short-term lithium-treated group. 3. Serum PRL values in the long-term Li-treated group were significantly lower than those of the control group, while there was no significant difference in PRL values between the short-term Li-treated group and the control group. 4. Our study documents that short-term (<6 months) Li treatment does not induce any significant changes in PRL release in bipolar patients compared to normal control subjects while long-term Li treatment (>6 months) leads to lower PRL release compared to the controls. Furthermore, PRL has wide intra-interindividual and circadian variations Li-PRL relationship seems to be very complex and probably depends on various interactions among dopamine, serotonin and PRL. Therefore, further studies are needed to confirm the data.


Assuntos
Transtorno Bipolar/tratamento farmacológico , Carbonato de Lítio/uso terapêutico , Prolactina/sangue , Adulto , Antimaníacos/uso terapêutico , Transtorno Bipolar/sangue , Eritrócitos/metabolismo , Humanos , Lítio/sangue , Masculino , Prolactina/metabolismo , Valores de Referência , Fatores de Tempo
7.
Biol Psychiatry ; 48(11): 1116-7, 2000 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-11094147

RESUMO

BACKGROUND: There are few reports describing chromosomal abnormalities in transsexuals. In rare cases, transsexualism and sexual chromosomal multiplicity coexist. Six cases of male-to-female transsexuals with 47,XYY chromosomal pattern have been previously reported. We have not encountered any female transsexual cases with 47,XXX karyotype in the literature. METHODS: A 21-year-old female patient came to our outpatient department with depressive symptoms and suicidal thoughts. On psychiatric interview, she reported that she had feelings of discomfort with her gender identity and had desired to be male since her childhood. Then, we performed cytogenetic investigation using blood culture and G chromosome banding. RESULTS: Histology and DNA histograms of the patient revealed a chromosomal pattern of 47,XXX. CONCLUSIONS: We conclude that sexual chromosomal abnormalities in some transsexuals may cause a vulnerability to development of a gender identity disorder.


Assuntos
Identidade de Gênero , Homossexualidade Feminina/genética , Aberrações dos Cromossomos Sexuais , Transexualidade/genética , Cromossomo X/genética , Adulto , Depressão/etiologia , Feminino , Predisposição Genética para Doença , Homossexualidade Feminina/psicologia , Humanos , Inteligência , Cariotipagem , Transexualidade/psicologia
8.
Transplantation ; 68(10): 1503-11, 1999 Nov 27.
Artigo em Inglês | MEDLINE | ID: mdl-10589947

RESUMO

UNLABELLED: Hepatitis B may take a rapid and aggressive course in patients under immunosuppression. Nucleoside analogues have been shown to suppress viral replication effectively. To investigate the effect of famciclovir in immunosuppressed patients, 21 heart transplant recipients with chronic hepatitis B infection were included in a prospective study. PATIENTS AND METHODS: Patients have been treated with Famciclovir for a median of 14 months. Hepatitis B virus replication and biochemical parameters were regularly tested and liver biopsies were taken before treatment and after a median time of 7 months. HBV-polymerase was sequenced in all patients before therapy and in those patients who experienced virological breakthrough. RESULTS: Nineteen patients were treated for at least 6 months. Hepatitis B virus-DNA levels declined in all patients and became negative in 8 patients. Mean hepatitis B virus-DNA levels decreased from 199+/-269 to 34+/-53 pg/ml after 24 weeks (P=0.003). During treatment HBeAg became negative in five patients. Mean alanine aminotransferase decreased from 42+/-26 to 24+/-10 U/L (P=0.006). Histological analysis revealed improved inflammatory activity according to the Ishak-score in 11/16 (69%) patients. Total inflammatory activity scores decreased from 8 to 6 (median, NS), but interface hepatitis score (P=0.02) and lobular inflammation score (P=0.006) improved significantly. Median fibrosis scores fell from 5 to 3 (P=0.002). Three patients developed virological breakthrough on famciclovir after 7, 8, and 26 months of treatment showing HBV-polymerase amino acid changes L528 M, S567A, and I581K, respectively. CONCLUSIONS: Famciclovir improves not only biochemical and virological features but also hepatic inflammation and liver fibrosis in patients with chronic hepatitis B under heavy immunosuppression. Virological breakthrough may develop and requires close monitoring.


Assuntos
2-Aminopurina/análogos & derivados , Antivirais/uso terapêutico , Transplante de Coração , Hepatite B Crônica/tratamento farmacológico , Complicações Pós-Operatórias/tratamento farmacológico , Pró-Fármacos/uso terapêutico , 2-Aminopurina/uso terapêutico , Adulto , Idoso , Alanina Transaminase/sangue , DNA Viral/sangue , Quimioterapia Combinada , Famciclovir , Feminino , Transplante de Coração/imunologia , Vírus da Hepatite B/isolamento & purificação , Humanos , Imunossupressores/uso terapêutico , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Fatores de Tempo
9.
Eur J Nucl Med ; 25(6): 601-6, 1998 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-9618574

RESUMO

We have not encountered any brain single-photon emission tomography (SPET) study performed in adolescent depressed patients in the literature. Therefore, we used technetium-99m hexamethylpropylene amine oxime (99mTc-HMPAO) brain SPET in adolescent patients with major depressive disorder (MDD) to examine the possible changes in cerebral perfusion and the possible association between perfusion indices and clinical variables. Fourteen adolescent out-patients (nine females, five males; mean+/-SD age: 13.11+/-1.43 years; range: 11-15 years) fulfilling the DSM-IV criteria for MDD and 11 age-matched healthy control subjects (six females, five males; mean+/-SD age: 13.80+/-1.60 years; range: 12-15 years) were included in the study. 99Tc-HMPAO brain SPET was performed twice in the patient group and once in the control group. The first SPET investigation was performed under non-medicated conditions and the second was performed after depressive symptoms had subsided. A relative perfusion index (PI) was calculated as the ratio of regional cortical activity to the whole brain activity. We found significant differences between the PI values of the untreated depressed patients and those of the controls, indicating relatively reduced perfusion in the left anterofrontal and left temporal cortical areas. No significant differences in regional PI values were found between the remitted depressed patients and the controls. Our study suggests that adolescent patients with MDD may have regional cerebral blood flow deficits in frontal regions and a greater anterofrontal right-left perfusion asymmetry compared with normal subjects. The fact that these abnormalities in perfusion indices have a trend toward normal values with symptomatic improvement suggests that they may be state-dependent markers for adolescent MDD.


Assuntos
Encéfalo/diagnóstico por imagem , Transtorno Depressivo/diagnóstico por imagem , Compostos Radiofarmacêuticos , Tecnécio Tc 99m Exametazima , Tomografia Computadorizada de Emissão de Fóton Único , Adolescente , Encéfalo/irrigação sanguínea , Estudos de Casos e Controles , Circulação Cerebrovascular/fisiologia , Transtorno Depressivo/fisiopatologia , Feminino , Humanos , Masculino
10.
Psychiatry Res ; 59(1-2): 165-70, 1995 Nov 29.
Artigo em Inglês | MEDLINE | ID: mdl-8771233

RESUMO

The activity of monoamine oxidase (MAO) and dopamine-beta-hydroxylase (DBH), enzymes involved in monoamine metabolism, were studied in 29 bipolar patients (mean age = 33.12 years, SD = 7.27) who were treated with lithium carbonate and in 20 healthy volunteers (mean age = 30.05 years, SD = 6.04). Platelet MAO activity was higher after lithium withdrawal, whereas plasma DBH activity was lower in remitted euthymic bipolar patients compared with normal volunteers. During lithium treatment, platelet MAO activity decreased and plasma DBH activity increased compared with the lithium-withdrawal values. It was also observed that the activities of these enzymes in the bipolar patients during lithium treatment did not differ from those in the volunteers. Thus, platelet MAO and plasma DBH activities differed in unmedicated patients with bipolar affective disorder from those of healthy subjects. Treatment with lithium appeared to have a normalizing effect on MAO and DBH activity levels.


Assuntos
Antimaníacos/uso terapêutico , Transtorno Bipolar/tratamento farmacológico , Plaquetas/efeitos dos fármacos , Dopamina beta-Hidroxilase/sangue , Carbonato de Lítio/uso terapêutico , Monoaminoxidase/sangue , Adulto , Antimaníacos/efeitos adversos , Transtorno Bipolar/enzimologia , Plaquetas/enzimologia , Feminino , Humanos , Carbonato de Lítio/efeitos adversos , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , Valores de Referência , Síndrome de Abstinência a Substâncias/enzimologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...